Unlocking the full potential of complement therapeutics through the power of selectivity.
2 - 10
π° $100M Private Equity Round on 2022-04
August 31
π‘ Remote β Anywhere in California
β° Full Time
π Senior
βοΈ Operations
July 26
π΄ Lead
July 25